These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9241663)

  • 21. Association of C609T-Inborn Polymorphism of NAD(P)H: Quinone Oxidoreductase 1 with the Risk of Bronchopulmonary Dysplasia in Preterm Neonates.
    Gavrili S; Zachaki S; Daraki A; Polycarpou E; Manola K; Stavropoulou C; Sambani C; Baroutis G
    Am J Perinatol; 2016 May; 33(6):535-9. PubMed ID: 26683602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Association between NAD(P)H: quinone oxidoreductase and apolipoprotein E gene polymorphisms in Alzheimer's disease].
    Ma QL; Yang JF; Shao M; Dong XM; Chen B
    Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(24):2124-7. PubMed ID: 14720419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis.
    Chao C; Zhang ZF; Berthiller J; Boffetta P; Hashibe M
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):979-87. PubMed ID: 16702380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The NAD(P)H:quinone oxidoreductase locus in human colon carcinoma HCT 116 cells resistant to mitomycin C.
    Hu LT; Stamberg J; Pan S
    Cancer Res; 1996 Nov; 56(22):5253-9. PubMed ID: 8912865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Relationship between quinone oxidoreductase1 gene ns-cSNP and genetic susceptibility of esophageal cancer].
    Zhang WC; Yin LH; Pu YP; Liang GY; Hu X; Liu YZ; Cui YS
    Zhonghua Yu Fang Yi Xue Za Zhi; 2006 Sep; 40(5):324-7. PubMed ID: 17166422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1.
    Siegel D; McGuinness SM; Winski SL; Ross D
    Pharmacogenetics; 1999 Feb; 9(1):113-21. PubMed ID: 10208650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of point mutation in exon 2 of CYP2E1 gene in renal cell/urothelial cancer patients in comparison with control population.
    Farker K; Lehmann MH; Kästner R; Weber J; Janitzky V; Schubert J; Hoffmann A
    Int J Clin Pharmacol Ther; 2000 Jan; 38(1):30-4. PubMed ID: 10667834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract.
    Sarbia M; Bitzer M; Siegel D; Ross D; Schulz WA; Zotz RB; Kiel S; Geddert H; Kandemir Y; Walter A; Willers R; Gabbert HE
    Int J Cancer; 2003 Nov; 107(3):381-6. PubMed ID: 14506737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase).
    Traver RD; Siegel D; Beall HD; Phillips RM; Gibson NW; Franklin WA; Ross D
    Br J Cancer; 1997; 75(1):69-75. PubMed ID: 9000600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators.
    Wiemels JL; Pagnamenta A; Taylor GM; Eden OB; Alexander FE; Greaves MF
    Cancer Res; 1999 Aug; 59(16):4095-9. PubMed ID: 10463613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No association between Helicobacter pylori seropositivity and ornithine decarboxylase (ODC) A317G polymorphism, and no modification by NAD(P)H:qinone oxidoreductase 1 (NQO1) C609T.
    Goto Y; Nishio K; Ishida Y; Kawai S; Osafune T; Naito M; Katsuda N; Hamajima N
    Nagoya J Med Sci; 2007 Jan; 69(1-2):17-22. PubMed ID: 17378176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan.
    Wang YH; Lee YH; Tseng PT; Shen CH; Chiou HY
    J Cancer Res Clin Oncol; 2008 Feb; 134(2):203-9. PubMed ID: 17619904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic association of NAD(P)H quinone oxidoreductase (NQO1*2) polymorphism with NQO1 levels and risk of diabetic nephropathy.
    Sharma M; Mehndiratta M; Gupta S; Kalra OP; Shukla R; Gambhir JK
    Biol Chem; 2016 Aug; 397(8):725-30. PubMed ID: 27078674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in prostate cancer.
    Ergen HA; Gormus U; Narter F; Zeybek U; Bulgurcuoglu S; Isbir T
    Anticancer Res; 2007; 27(6B):4107-10. PubMed ID: 18225579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves.
    Chung JE; Chang BC; Lee KE; Kim JH; Gwak HS
    Eur J Clin Pharmacol; 2015 Oct; 71(10):1229-36. PubMed ID: 26257249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C.
    Fleming RA; Drees J; Loggie BW; Russell GB; Geisinger KR; Morris RT; Sachs D; McQuellon RP
    Pharmacogenetics; 2002 Jan; 12(1):31-7. PubMed ID: 11773862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High throughput genotyping for the detection of a single nucleotide polymorphism in NAD(P)H quinone oxidoreductase (DT diaphorase) using TaqMan probes.
    Shi MM; Myrand SP; Bleavins MR; de la Iglesia FA
    Mol Pathol; 1999 Oct; 52(5):295-9. PubMed ID: 10748880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia.
    Pae CU; Yu HS; Kim JJ; Lee CU; Lee SJ; Jun TY; Lee C; Paik IH
    Int J Neuropsychopharmacol; 2004 Dec; 7(4):495-500. PubMed ID: 15151706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implication of alternative splicing for expression of a variant NAD(P)H:quinone oxidoreductase-1 with a single nucleotide polymorphism at 465C>T.
    Pan SS; Han Y; Farabaugh P; Xia H
    Pharmacogenetics; 2002 Aug; 12(6):479-88. PubMed ID: 12172217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No associations between Parkinson's disease and polymorphisms of the quinone oxidoreductase (NQO1, NQO2) genes.
    Okada S; Farin FM; Stapleton P; Viernes H; Quigley SD; Powers KM; Smith-Weller T; Franklin GM; Longstreth WT; Swanson PD; Checkoway H
    Neurosci Lett; 2005 Mar; 375(3):178-80. PubMed ID: 15694256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.